Developing Thailand with the BCG economic model aims to drive the Thai economy to sustainability in all dimensions. One of the important fields –medicine and vaccines – is being supported by relevant agencies, especially in “biopharmacy development,” which still has access problems. As the drugs are high-priced, the country’s goal is to produce nine biological medicines within five years, which means that it will be able to reduce imports by 7,500 million baht and increase the ability to export medicines worth 10 billion baht, which Thailand has never been able to do before. Given below are the directions it will be driven:
- To promote the establishment of antibody drug production centers in countries that meet specific standards;
- To develop biopharma engineering courses in educational institutions, in order to enter the pharmaceutical industry;
- To develop personnel that will be connected with the research section of the manufacturing industry and the marketing of the pharmaceutical industry;
- To set up a budget to support further studies at the master's/ doctoral level in Thailand and abroad, including study visits on production and product quality control;
- To establish a consulting unit for domestic manufacturers from the beginning of the research process, and study the path from beginning to end to prepare registration information;
- To provide channels to contact for advice from the FDA and National Guidelines issued by the government sector to provide advice on drug development, drug production, and drug registration;
- To improve privileges such as terms and conditions and short-term loans by relaxing loan conditions and repayment periods, as well as extending the period of corporate income tax exemption privileges appropriately;
- To find sources of funding to support the initial stage before starting.
Source: National Science and Technology Development Agency (NSTDA)
Tel: +66 2 564 8000
EN
CN
DE
JP
TH
